Clinical trials: Relapsing Remitting Multiple Sclerosis
Multiple Sclerosis
Cognitive Effects of Immunomodulatory Drugs in MS
The purpose of this study is to examine and compare changes in the specific thinking skills of patients with RRMS who are receiving treatment with one of three immunomodulatory medications (Avonex, Copaxone, or Rebif).
- Trial name
- NCT00229502
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Sharon Lynch, MD
Pediatric Multiple Sclerosis
Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis
The purpose of this study is to better understand multiple sclerosis (MS) in children and adolescents, to learn if it differs from adult MS and to investigate if genes or environmental exposures or a combination of both put…
- Trial name
- NCT01396343
- Where
- 17 sites in United States
- Volunteers
- 1,276 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
MS-ResearchBiomarkerS
This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- MS-ReBS (NCT05204459)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Multiple Sclerosis, Relapsing-Remitting, Healthy Controls
The Relationships Between Personal Identity, Autobiographical Memory and Future Thinking in People With Multiple Sclerosis
Personal identity is composed of multiple facets of the self that are constructed and nourished through memories of past experiences (i.e., autobiographical memory) and the imagination of events that may occur in the future…
- Trial name
- SELFSEP (NCT05648292)
- Testing
- Neuropsychological tests and psychological questionnaires
- Where
- France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Centre d'Investigation Clinique et Technologique 805
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Cortical Lesions in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune disease, leading to inflammation and degeneration of neurons in the entire central nervous system (CNS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- CLiMS (NCT03653585)
- Where
- Denmark
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Danish Research Centre for Magnetic Resonance
Multiple Sclerosis, RRMS
Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis
The main purpose of this study is to assess whether hyperpolarized carbon imaging in relapsing remitting multiple sclerosis (MS) patients can be used to predict response to anti-CD20 disease modifying therapy.
- Conditions
- Multiple Sclerosis, RRMS, Relapsing Remitting MS
- Trial name
- MIIMS (NCT07510607)
- Testing
- HP 13C pyruvate injection, MRI Scanner
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ari Green
Multiple Sclerosis (MS), Relapsing-remitting Multiple Sclerosis (RRMS)
Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
This project is to: 1. Quantify differences in axonal integrity and organization in aMS versus naPMS patients. 2. Quantify changes in axonal integrity and organization in aMS versus naPMS patients over a two-year period. 3.
- Conditions
- Multiple Sclerosis (MS), Relapsing-remitting Multiple Sclerosis (RRMS), Secondary-progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS)
- Trial name
- INsIDER (NCT05177523)
- Testing
- MRI, Neurocognitive examination for healthy subjects, blood sampling
- Where
- Switzerland
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Anxiety
Effectiveness of a Schema Therapy on Anxiety in Patients With Multiple Sclerosis
It is a multicentric randomized and controlled study comparing a Scheme therapy program versus local practice in RRMS patients with anxiety.
- Trial name
- NCT04030819
- Testing
- schema therapy
- Where
- France
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Paris Nanterre University
Multiple Sclerosis, Relapsing-Remitting
Phase I BP Interferon (IFN) Beta-001
Phase I study aiming at: assessing the absolute bioavailability, pharmacokinetic profile, and dose proportionality of interferon beta-1a (HSA-free solution in pre-filled syringes) after i.v. and s.c.
- Trial name
- NCT02515695
- Testing
- Interferon beta-1a
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Multiple Sclerosis, Relapsing-Remitting
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.
GSK2018682 is a potent and selective agonist for the sphingosine-1- phosphate receptor subtype 1 (S1P1) with the potential to be an effective treatment for multiple sclerosis (MS).
- Trial name
- P1A114919 (NCT01466322)
- Testing
- GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cognition, Brain Volume Loss
Effect of Fingolimod on Neurodegeneration
This was a 24-month, open-label, multicenter study with a single treatment arm design. Primary objective of this study was: -To investigate the effects of Fingolimod on cognitive performance in highly active relapsing remitting…
- Trial name
- NCT02575365
- Testing
- 0,5 mg Fingolimod
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)
The study is a two-year prospective observational study of patients treated with teriflunomide. The investigators will recruit up to 75 patients at baseline, based on the estimate that approximately 20% of these patients (~ 15…
- Trial name
- NCT03561402
- Testing
- Teriflunomide
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- McGill University
Multiple Sclerosis-Relapsing-Remitting
Speech in Noise Discrimination Skills in Multiple Sclerosis Patients.
The aim of this clinical trial was to determine the effect of multiple sclerosis on speech reception and discrimination in noise and to compare the effects on the medial olivocochlear reflex, which is thought to affect speech…
- Trial name
- NCT06381297
- Testing
- Hearing test, Speech in noise discrimination test, Montreal Cognitive Assessment Scale
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Asuman Kucukoner
Multiple Sclerosis, Remitting Relapsing Multiple Sclerosis
Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis
Multiple sclerosis (MS) is the most frequently acquired demyelinating disease and the first cause of non-traumatic chronic disability in young adults.
- Trial name
- MODIF-MS (NCT06330077)
- Testing
- Ifenprodil
- Where
- 2 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Sclerosis, Relapsing-Remitting
Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers
The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat ascending doses of GSK2018682.
- Trial name
- P1A114347 (NCT01431937)
- Testing
- GSK2018682
- Where
- 3 sites in Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Relapse Remitting Multiple Sclerosis
Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis
The purpose of this research is to find out how the T regulatory (Treg) cells control autoimmune response in multiple sclerosis.
- Trial name
- NCT04857489
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Relapsing Remitting Multiple Sclerosis
Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects
The primary objective of this study was to assess the bioequivalence of the test product (Bafiertam; BLS-11; monomethyl fumarate) 190 mg versus Tecfidera® (dimethyl fumarate) 240 mg based on the Cmax and Area Under the Curve…
- Trial name
- NCT04570670
- Testing
- monomethyl fumarate 190 mg, dimethyl fumarate 240 mg
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Banner Life Sciences LLC
Multiple Sclerosis (MS) - Relapsing-remitting
Educational Programs Based on Healthy Habits to Improve Quality of Life and Psychosocial Profile in Women With Neurodegenerative Diseases: The ADVICE Protocol Study (Phase 1)
This phase of the project aims to analyze the interaction between physical exercise and the phases of the menstrual cycle, evaluating its impact on fatigue, functional capacity, and exercise perception in women with and without…
- Trial name
- ADVICE Phase 1 (NCT06925022)
- Testing
- Strength training session during Early Follicular Phase, Strength Training Protocol during Late Follicular Phase, Strength Training during Mid-Luteal Phase
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Universidad de Almeria
Multiple Sclerosis, Relapsing-Remitting
Healthy Volunteer Study Using 3 Different Formulations of Firategrast
This study will investigate how 3 types of drug formulations are absorbed by the body. This study is termed 'open-label', which means volunteers will be aware of which treatment they are receiving.
- Trial name
- NCT01416363
- Testing
- Firategrast immediate release tablet, Firategrast modified release tablet, Firategrast gastro-retentive solution
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis, Clinically Isolated Syndrome
Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis
This project aims to analyze ocular motility problems, visual processing speed and microperimetry, and their relationship with consolidated retinal structural biomarkers (optical coherence tomography, OCT) in patients with…
- Conditions
- Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis
- Trial name
- NCT05706220
- Testing
- Eye tracking, Microperimetry, Optical coherence tomography (OCT)
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA